Lori D Bash
Overview
Explore the profile of Lori D Bash including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1186
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Greene S, Bash L, Tebbs K, Hancock L, Barlow S, Coyle C
JACC Heart Fail
. 2024 Sep;
12(12):2120-2122.
PMID: 39297863
No abstract available.
2.
Coyle C, Bash L, Ramey D, Atkins G, Barash I, Guedes M, et al.
Kidney Int Rep
. 2024 Sep;
9(9):2814-2818.
PMID: 39291210
No abstract available.
3.
Turzhitsky V, Bash L, Urman R, Kattan M, Hofer I
JMIR Perioper Med
. 2024 Jul;
7:e52278.
PMID: 39038283
Background: Neuromuscular blockade (NMB) agents are a critical component of balanced anesthesia. NMB reversal methods can include spontaneous reversal, sugammadex, or neostigmine and the choice of reversal strategy can depend...
4.
Gaggin H, Greene S, Zhou M, Lautsch D, Bash L, Djatche L, et al.
Int J Cardiol Cardiovasc Risk Prev
. 2024 May;
21:200278.
PMID: 38766664
Background: Based on available data from randomized clinical trials, patients with heart failure with reduced ejection fraction (HFrEF) and worsening HF events (WHFE) have substantial disease burden and poor outcomes....
5.
Greene S, Gaggin H, Zhou M, Bash L, Lautsch D, Djatche L, et al.
ESC Heart Fail
. 2024 Apr;
11(4):1932-1946.
PMID: 38639469
Aims: Patients with HFrEF and worsening HF events (WHFE) are at particularly high risk and urgently need disease-modifying therapy. CHART-HF assessed treatment patterns and reasons for medication decisions among HFrEF...
6.
Krijtenburg P, Boer A, Bash L, Scheffer G, Keijzer C, Warle M
Perioper Med (Lond)
. 2024 Mar;
13(1):22.
PMID: 38539254
Background: Residual neuromuscular blockade (rNMB) remains a persistent and preventable problem, with serious risks. Methods: Our objective was to describe and assess patterns in the use of neuromuscular blocking agents...
7.
Bash L, Turzhitsky V, Mark R, Hofer I, Weingarten T
J Clin Anesth
. 2024 Mar;
96:111423.
PMID: 38503680
No abstract available.
8.
Bash L, Turzhitsky V, Mark R, Hofer I, Weingarten T
J Clin Anesth
. 2023 Nov;
93:111344.
PMID: 38007845
Study Objective: Perioperative neuromuscular blocking agents are pharmacologically reversed to minimize complications associated with residual neuromuscular block. Neuromuscular block reversal with anticholinesterases (e.g., neostigmine) require coadministration of an anticholinergic agent...
9.
Greco M, Caruso P, Angelotti G, Aceto R, Coppalini G, Martinetti N, et al.
J Clin Med
. 2023 Jan;
12(2).
PMID: 36675492
Background: Neuromuscular blocking agent (NMBA) monitoring and reversals are key to avoiding residual curarization and improving patient outcomes. Sugammadex is a NMBA reversal with favorable pharmacological properties. There is a...
10.
Colquhoun D, Vaughn M, Bash L, Janda A, Shah N, Ghaferi A, et al.
Br J Anaesth
. 2022 Jun;
130(1):e148-e159.
PMID: 35691703
Background: Postoperative pulmonary complications are a source of morbidity after major surgery. In patients at increased risk of postoperative pulmonary complications we sought to assess the association between neuromuscular blocking...